Navigation Links
Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
Date:9/14/2009

SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The results showed that vicriviroc plus optimized background therapy achieved durable virologic suppression and increased CD4 cell counts, and was generally well tolerated over two years of therapy. These 96-week results were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).(1)

The study involved 85 treatment-experienced HIV-infected patients who received 48 weeks of open-label vicriviroc (30 mg once daily) plus an optimized antiretroviral regimen containing a ritonavir-boosted protease inhibitor after completion of 48 weeks of treatment in the double-blind phase of the VICTOR-E1 study (total of 96 weeks). More than half of these patients began open-label treatment with undetectable virus, i.e. an HIV-1 RNA level of less than 50 copies/mL, and about two-thirds had less than 400 copies/mL. Seventy patients remained on therapy at the time of the 96-week analysis. The virologic effect seen during the double-blind phase of the study was sustained in these patients during open-label vicriviroc treatment, with the percentage of patients achieving undetectable virus increasing over the course of therapy. Importantly, further improvements in CD4 counts were observed with longer vicriviroc therapy, with a mean increase of 50 cells/mm3 from week 48 of the double-blind study to the end of the 96-week period.

The data also showed that vicriviroc was generally well tolerated in this highly treatment-experienced population.
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
2. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
3. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
4. Schering-Plough Announces Results of the Early ACS Trial
5. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
6. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
9. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
10. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
11. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Nonin Medical, a global leader in noninvasive medical monitoring, ... Steve Bucholz will retire May 1. Company founder ... Chief Executive Officer. In addition, Mr. Isaacson will continue ... transition to David Noel , Chief Financial Officer. ... to Nonin Medical,s growth," Mr. Isaacson said. "Under Steve,s ...
(Date:4/17/2015)... R.I , April 17, 2015 CVS ... a conference call on Friday, May 1, 2015, at ... its first quarter financial results. An audio ... through the Investor Relations portion of the CVS Health ... visit http://investors.cvshealth.com . This webcast will be archived ...
(Date:4/17/2015)... ASSESS shows   plasma circulating tumour DNA (ctDNA) ... tumour biopsy   IGNITE supports value of ... AstraZeneca today presented results from two key studies ... for epidermal growth factor receptor (EGFR) mutation status in newly ... clinical practice. [ 1 ] , ...
Breaking Medicine Technology:Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... AUG. 2 Two major studies,published today in The ... pregnant women at risk for preterm delivery who can ... today. In one large multi-center trial led by ... whom had no prior history of preterm birth) who,received ...
... Population of Glioblastoma Patients Expected to Support ... Promising New Approach -, TUSTIN, Calif., Aug. 2 ... stage biopharmaceutical,company developing targeted monoclonal antibodies for the treatment ... the first,patient has been administered Cotara(R) in a new ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
(Date:4/19/2015)... Philadelphia, Pennslyvania (PRWEB) April 19, 2015 ... and proved tolerable in a small group of healthy ... (UPCI), partner with UPMC CancerCenter , announced ... (AACR) Annual Meeting in Philadelphia. , The ... clinical trial, which will recruit participants at high risk ...
(Date:4/19/2015)... 2015 New court documents issued by ... that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) continue to mount ... District of South Carolina. According to the April 15th ... in the proceeding on behalf of individuals who allegedly ... the cholesterol-lowering statin. This represents an increase of 110 ...
(Date:4/19/2015)... April 19, 2015 Family and friends of ... Brains in Memory of Brad Baddeley event to honor ... Foundation. , Bowling for Brains is cheduled to take place ... Dudley Street in Lincoln, Nebraska. Participants may arrive at 12:30pm ... 3:00pm. , The cost is only $4 per game and ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancequotesinfo.com has ... insurance can cover physical injuries caused by a ... excellent financial coverage for a vehicle. A policy can ... by an accident. Drivers should always carry appropriate coverage ... insurance policy can be bought with several important riders ...
(Date:4/18/2015)... 2015 Review of Ophthalmology magazine and ... for Success’ program for cataract surgeons attending the American ... Diego, where eye surgeon Jeffrey L. Martin, MD will ... Dr. Martin is the Managing Partner of North Shore ... Dr. Martin to lead this year’s discussion on the ...
Breaking Medicine News(10 mins):Health News:Preventing Cancer with Broccoli Sprout Extract 2Health News:Preventing Cancer with Broccoli Sprout Extract 3Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2
... Thursday asked the government, the railway ministry and the Indian ... petition accusing them of supplying unhygienic food to rail passengers.// ... Khetrapal issued notice to the respondents to file their replies ... entrusted with the task of supplying food to passengers on ...
... Society Wolfson Research Professor and inventor of DNA Fingerprinting ... which will be awarded to him later this year. ... Heineken Prize for Biochemistry and Biophysics 2006 by the ... of the discovery of the revolutionary technique. ...
... shake-up of the out of hours health care system in England ... ,The public accounts committee claimed that the new health ... met many key targets. ,In 2004 most GPs had ... which PCTs took over in 90% of cases. ,The ...
... launched by the Cancer Research UK, and its ... take up// drug candidates that pharmaceuticals companies have ... their preclinical studies. By this they plan to ... been shelved by pharmaceutical and biotechnology companies. ...
... and Aberdeen University in Scotland found that women with ... have twins// following in vitro fertilization. They found that ... multiple births after fertility treatment. ,However, the ... protects against birth defects such as spina bifida, does ...
... Embryology Authority show that recently there is a surge ... technology// (ART) in the UK. It is astonishing to ... 34. There is increase in women choosing to delay ... and scientists say that there are long-term risks associated ...
Cached Medicine News:Health News:Inventor of DNA fingerprinting Wins Accolades 2Health News:Cancer Research UK Offers New Hope To Cancer Patients 2Health News:High Levels Of Folic Acid May Increase The Chances Of Twins After IVF 2
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Detection of Malarial antigen in Human whole blood....
Medicine Products: